NCT00513058View on ClinicalTrials.gov

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

April 30, 2012

Conditions
Breast Cancer
Interventions
DRUG

Lapatinib

Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d

DRUG

vinorelbine

DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2

Trial Locations (5)

21079

Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon

31052

Institut Claudius Regaud, Toulouse

59020

Centre Oscar Lambret, Lille

75248

Institut Curie Hopital, Paris

92211

Centre Rene Huguenin, Saint-Cloud

All Listed Sponsors
lead

UNICANCER

OTHER

NCT00513058 - Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter